Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
Hyon‐Jo Kwon(Center for Biologics Evaluation and Research), M. Miles Braun(Georgetown University), Michael S. Cuffe(United States Food and Drug Administration), Timothy R. Cot(United States Food and Drug Administration), Judith M. Kramer(United States Food and Drug Administration)
Cited by 459
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
|PubMed|2003|397
<i>Listeria monocytogenes</i> infection as a complication of treatment with tumor necrosis factor α–neutralizing agents
|Arthritis & Rheumatism|2003|387